Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM ESTRBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $6.00 (from $8.00) while maintaining a Sector Perform rating. DEPO reported a 3Q top-line miss and another 2017E guidance step-down. Revenue came in at ~$95 million, below consensus of ~$99 million. Guidance was again lowered by $2030 million to... More



